GlaxoSmithKline’s entire stake in Innoviva was sold back to the U.S.-based biopharmaceutical company for about $392 million, the British drugmaker said on May 20, as GSK simplifies operations ahead of a split into two businesses.
Germany’s CureVac, which is gearing up to publish results of a key Covid-19 vaccine trial, said U.S. export restrictions on key materials are making it impossible to predict the company’s short-term supply ramp-up in Europe.
Roivant Sciences is combining with Montes Archimedes Acquisition Corp (MAAC), a particular purpose acquisition company sponsored by Patient Square Capital.
After filing plans for an initial public offering earlier in April, U.K.-based Vaccitech raised $110.5 million in the company’s IPO and on April 30 announced the pricing of 6.5 million American Depositary Shares at $17 per share.
Clarus Therapeutics Inc. and Blue Water Acquisition Corp. on April 27 announced a definitive business combination agreement that will result in Clarus becoming a publicly traded company.
Three biopharma companies became publicly traded companies and made their debut on the Nasdaq this week.
Cerevel Therapeutics began trading on the Nasdaq.
Neurotrope and Metuchen Pharmaceuticals announced the companies have merged in an all-stock deal to form Petros Pharmaceuticals, which is focused on men’s health conditions.
Amgen filed a Worker Adjustment and Retraining in California with plans to cut 172 jobs at the company’s headquarters and U.S. field operations effective December 31, 2019.
South San Francisco-based Harpoon Therapeutics is tapping into the white-hot IPO magic that was one of the hallmarks of 2018 for the biotech industry.